ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza

While most pathogens infect via mucosal surfaces, most current vaccines are delivered by injection. This situation remains despite awareness of the potential benefits of mucosal delivery for inducing protection against mucosa-infecting pathogens. A major obstacle to the development of such vaccines...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hum Vaccin Immunother
Autori principali: Timothy, Andrea A, Tokanovic, Ana, Snibson, Kenneth J, Edwards, Stirling J, Pearse, Martin J, Scheerlinck, Jean-Pierre Y, Sutton, Philip
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2015
Soggetti:
INFLUENZA/Research Papers
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4514340/
https://ncbi.nlm.nih.gov/pubmed/25692970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/21645515.2014.990859
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi